Future Fertility adds new partner Apricity Fertility on the heels of achieving UK regulatory approval

Future Fertility has received UK regulatory approval for its AI-based oocyte assessment software, expanding UK footprint in partnership with Apricity Fertility.

Future Fertility develops AI-powered solutions that empower fertility patients and their providers with personalised insights to help optimise the fertility journey.

The company’s AI decision support software for oocyte (human egg) quality assessment has achieved UK compliance for commercial use across the UK.

Future Fertility previously received CE Mark approval in the summer of 2022. Now, this UK achievement further solidifies their commercial presence in Europe.

Its Oocyte Software is the first and only non-invasive, clinically validated tool to use artificial intelligence to analyse 2D images of oocytes and generate personalised insights about egg quality.

In today’s standard of care, fertility specialists and embryologists make judgments about egg quality based on a patient’s age group, but this doesn’t account for the variability between patients in the same age group, especially among younger patients.

Through VIOLET™ (for egg freezing patients) and MAGENTA™ (for IVF-ICSI patients), patients and providers can understand the likelihood of each retrieved egg developing to a day 5/6 embryo (eligible for blastocyst transfer), which helps to manage expectations for success and optimise treatment plans.

Future Fertility has already teamed up with leading-edge clinics to integrate their AI solutions and provide the best patient care.

As a longstanding collaborator and partner to the CARE Fertility clinic group, the technology has proven to be scientifically valid and useful to the patient experience.

As Future Fertility expands their UK footprint, they are proud to announce a new partnership with their first virtual clinic partner, Apricity.

Apricity is the UK’s first virtual fertility clinic. Their unique virtual model and mobile app has reimagined the fertility journey, enabling patients to easily navigate each step of the fertility process with at-home solutions and access to world class specialists.

Its digital solution is designed to improve the fertility experience and maximise chances of conception via a fully-customised treatment journey for patients.

Apricity partners with a selected network of clinics around the UK to deliver required in-person treatments, bringing visits to a clinic down to two per cycle rather than ten as with a traditional journey.

“The UK is a leading market in fertility care, the birthplace of the first IVF baby,” says Future Fertility CEO, Christy Prada.

“We are proud to have strong partners in the UK and look forward to partnering with Apricity to bring our products to new patient groups and clinics across the region.”

Apricity and Future Fertility’s partnership will launch as a pilot programme, kicking off this year in cooperation with IVF London.

Oocyte assessment will be conducted via the IVF London lab using Future Fertility’s software, and results will be made available to patients to discuss with their fertility specialists.

Apricity CEO, Caroline Noublanche comments: “Apricity are excited to partner with Future Fertility on this pilot, which aligns with our ‘less stress & more success’ approach.

“‘Less stress’ as giving our patients a greater level of transparency on their oocytes and chances right after egg collection and ‘better success’ as complementing Apricity’s own AI and the amazing embryology team at IVF London to make the best informed choices and ultimately improve the chances of conception.”

For more info, visit futurefertility.com.